Elotuzumab Therapy for Relapsed or Refractory XXXX .

@entity1 @entity55 @entity2905 @entity1582 @entity619 @entity1398 @entity6985 @entity204
UNASSIGNED: Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with @entity6985 and @entity619 in a phase 1b-2 study in @entity1 with relapsed or refractory multiple @entity1582 . Methods In this phase 3 study, we randomly assigned @entity1 to receive either elotuzumab plus @entity6985 and @entity619 (elotuzumab group) or @entity6985 and @entity619 alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results Overall, 321 @entity1 were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or @entity204 in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were @entity2905 , @entity1398 , fatigue, and @entity55 . Infusion reactions occurred in 33 @entity1 (10%) in the elotuzumab group and were grade 1 or 2 in 29 @entity1 . Conclusions @entity1 with relapsed or refractory multiple @entity1582 who received a combination of elotuzumab, @entity6985 , and @entity619 had a significant relative reduction of 30% in the risk of disease progression or @entity204 . (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797 .).
